Hexarelin Research Overview
Hexarelin: the most potent synthetic GHRP, its dual GH-releasing and GH-independent cardiac protection mechanisms, and the CD36 receptor pathway that sets it apart from all other GHRPs.
Background and Classification
Hexarelin (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH₂) is a synthetic hexapeptide analogue of GHRP-6, developed by Europeptides in the early 1990s. The key structural modification relative to GHRP-6 is the substitution of D-2-methyltryptophan at position 2, which dramatically increases GHS-R1a binding affinity and agonist potency. In comparative studies, Hexarelin produces peak GH responses 2–4 times greater than equimolar GHRP-6 and is consistently the most potent GH-releasing peptide in the GHRP class on a molar basis.
However, Hexarelin's research significance extends considerably beyond its GH-releasing potency. The discovery that Hexarelin activates CD36 — a scavenger receptor expressed on cardiomyocytes, macrophages, and endothelial cells — through a GH-independent mechanism opened a distinct line of cardiovascular research that has no parallel in other GHRPs. This dual pharmacology positions Hexarelin as a uniquely informative research tool for dissecting GH-dependent from GH-independent effects of GHS-R1a agonism.
Sequence
His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH₂
Molecular Weight
887.1 Da
Primary Receptor
GHS-R1a (pituitary); CD36 (cardiac, immune)
GH Potency Relative to GHRP-6
2–4× greater (molar equivalent)
Half-life (plasma)
~30–70 minutes
Administration Route
Subcutaneous, intravenous (research)
GHS-R1a Mechanism and GH Release
Hexarelin activates GHS-R1a with higher receptor affinity and intrinsic efficacy than any other characterised synthetic GHRP. GHS-R1a activation in pituitary somatotrophs triggers phospholipase C–mediated IP₃ production, intracellular calcium mobilisation from the endoplasmic reticulum, and PKC activation — all converging on GH granule exocytosis. Hexarelin's D-2-methyltryptophan modification enhances hydrophobic contacts within the GHS-R1a binding pocket, explaining its superior potency.
In human studies, Hexarelin produces peak GH concentrations substantially higher than GHRP-6 at equivalent doses. However, this potency comes with a corresponding increase in off-target receptor activation. Hexarelin significantly elevates cortisol, ACTH, and prolactin — side effects that are minimal with Ipamorelin and moderate with GHRP-2. For research contexts where clean GH axis stimulation without corticotropic co-activation is the priority, Ipamorelin is preferred. For protocols where maximal GH pulse amplitude is the objective and hormonal side effects are acceptable confounders, Hexarelin's superior potency is an advantage.
Desensitisation: The Key Limitation
Hexarelin's most significant limitation for chronic research protocols is its tendency to produce rapid GHS-R1a desensitisation. With repeated daily administration, GH response to Hexarelin attenuates substantially within 1–2 weeks, an effect not observed to the same degree with GHRP-2 or Ipamorelin. The proposed mechanism involves both GHS-R1a downregulation (receptor internalisation following ligand binding) and post-receptor desensitisation of downstream signalling components. For short-term, high-intensity GH stimulation research, this is not limiting; for chronic administration models, it significantly restricts Hexarelin's utility.
The CD36 Receptor: A GH-Independent Cardioprotective Pathway
The most scientifically distinctive aspect of Hexarelin's pharmacology is its activation of CD36 — a class B scavenger receptor with broad expression in cardiomyocytes, macrophages, platelets, retinal pigment epithelium, and adipocytes. CD36 was identified as a Hexarelin binding site through radioligand binding studies in hypophysectomised animals (GH-deficient models) where Hexarelin retained cardiac activity despite absent pituitary GH release — definitively demonstrating a GH-independent cardiac mechanism.
Critical Distinction
Hexarelin is the only GHRP demonstrated to activate CD36 with sufficient affinity to produce measurable downstream cardiac effects. GHRP-2, GHRP-6, and Ipamorelin do not significantly activate CD36 at research doses. This makes Hexarelin uniquely suited for research designs that aim to study GH-independent cardiac peptide signalling, or that seek to separate GHS-R1a–mediated from CD36-mediated effects using selective antagonists or GH-deficient animal models.
CD36 Signalling in Cardiac Tissue
CD36 activation by Hexarelin in cardiomyocytes triggers ERK1/2 and PI3K/AKT signalling cascades that promote cell survival, reduce apoptosis, and attenuate the inflammatory response to ischaemic injury. In isolated perfused heart models (Langendorff preparation), Hexarelin administered before or during simulated ischaemia significantly reduces infarct size, improves post-ischaemic functional recovery (contractile force, coronary flow), and decreases lactate dehydrogenase release — a marker of cardiomyocyte death. Critically, these effects are replicated in GH-deficient animals and attenuated by CD36-blocking antibodies, confirming the GH-independent CD36 mechanism.
Cardiac Research: Key Findings
Ischaemia-Reperfusion Protection
Hexarelin's cardioprotective effects in ischaemia-reperfusion (I/R) models are among the most replicated findings in GHRP research. Multiple independent groups have demonstrated 30–50% reductions in infarct size with Hexarelin pretreatment in rodent I/R models, with improvements in ejection fraction and wall motion scores at 24–72 hours post-injury. The dual mechanism — GHS-R1a–mediated GH release (with downstream IGF-1 cardioprotection) and direct CD36 activation — likely contributes additive cardioprotective effects.
Anti-Fibrotic Effects in Heart Failure Models
In rat models of chronic heart failure induced by myocardial infarction, chronic Hexarelin administration reduced cardiac fibrosis as measured by hydroxyproline content and collagen I/III expression, and partially preserved left ventricular geometry and function compared to vehicle-treated infarcted controls. The anti-fibrotic mechanism appears to involve CD36-mediated suppression of TGF-β1 signalling and reduction of myofibroblast activation — pathways central to the maladaptive remodelling that drives progression of heart failure.
Atherosclerosis and Macrophage Research
CD36 is highly expressed in macrophages and plays a central role in foam cell formation — the lipid-laden macrophage phenotype that drives atherosclerotic plaque development. Hexarelin's CD36 activation in macrophages has paradoxically been associated with both lipid uptake (through its scavenger receptor function) and anti-inflammatory polarisation effects. Research has explored Hexarelin as a tool for studying CD36's complex dual roles in atherosclerosis biology.
Research Design Consideration
To distinguish GHS-R1a–mediated from CD36-mediated effects of Hexarelin in research models, the standard approach uses hypophysectomised (GH-deficient) animals or GHS-R1a knockout models. If Hexarelin's effect persists in the absence of GH, CD36 is implicated. If the effect is blocked by CD36 antibodies or absent in CD36 knockout models, the CD36 pathway is confirmed. This pharmacological dissection approach is essential for mechanistic interpretation of Hexarelin research data.
Comparison Within the GHRP Class
For researchers selecting between GHRPs, the choice of Hexarelin versus alternatives depends entirely on the research objective. Hexarelin is the correct choice when: maximum GH pulse amplitude is required in a short-duration protocol; GH-independent cardiac or CD36 biology is the primary research question; or the study design specifically requires the most potent available GHS-R1a agonist for receptor characterisation work. Ipamorelin is preferred when: a clean hormonal profile without cortisol/prolactin elevation is required; chronic multi-week administration is planned; or the research requires consistent, non-desensitising GH pulse stimulation.
Research Use Only — Disclaimer This document is prepared for laboratory and research reference purposes only. Hexarelin is not approved by the FDA for human therapeutic use. All information pertains to preclinical research models and published scientific literature. This content does not constitute medical advice, diagnosis, or treatment recommendation. Researchers must comply with all applicable institutional and jurisdictional regulations.
References
- Deghenghi R, et al. "GH-releasing activity of Hexarelin, a new growth hormone releasing peptide, in infant and adult rats." _Life Sci_. 1994;54(18):1321–1328.
- Bodart V, et al. "CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart." _Circ Res_. 2002;90(8):844–849.
- Bisi G, et al. "Hexarelin protection of cardiac function in experimental heart failure." _Growth Horm IGF Res_. 1999;9(Suppl B):S29–S33.
- Tivesten Å, et al. "The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction." _Endocrinology_. 2000;141(1):60–66.
- Muccioli G, et al. "Specific binding sites for growth hormone-releasing peptides in human brain and pituitary gland." _Eur J Pharmacol_. 1998;360(2–3):87–92.
- Rossoni G, et al. "Hexarelin protects against cardiac damage in a rat model of ischaemia and reperfusion through a GH-independent mechanism." _Growth Horm IGF Res_. 2007;17(5):418–425.